Back before Ironwood Pharmaceuticals Inc. showed the world that biotechs could make a go at initial public offerings (IPO), the reverse merger temporarily shed its less-than-desirable reputation. It became the exit du jour for private biotechs whose IPO bids were stymied by unfavorable market conditions and needed access to substantial cash. Read More
